💊 Is BA.2 worse? Some say yes. Others say no; Moderna enters the RSV queue; the US FDA gets busy

Feb 23, 2022

∙ Paid

In today’s Kable: Homology goes where BioMarin did; Moderna goes where many others did; BioNTech gets into oncology; Lilly goes big on gene therapies; GSK unveils Haleon; Iran returns vaccine doses; Evidence mounting that BA.2 is bad. Or not.

💊 Is BA.2 worse? Some say yes. Others say no; Moderna enters the RSV queue; the US FDA gets busy

This post is for paid subscribers